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Abstract  Small  bowel  evaluation  is  a  challenging  task  and  has  been  revolutionized  by
high-quality  contrasted  sectional  imaging  (CT  enterography  -  CTE)  and  magnetic  resonance
enterography  (MRE)  as  well  as  by  small  bowel  capsule  endoscopy  (SBCE).
The decision  of  which  technique  to  employ  during  the  investigation  of  small  bowel  diseases
is not  always  simple  or  straightforward.  Moreover,  contraindications  may  preclude  the  use  of
these techniques  in  some  patients,  and  although  they  are  noninvasive  procedures,  may  present
with various  complications.
SBCE  plays  a  crucial  role  in  the  investigation  of  both  obscure  gastrointestinal  bleeding  and
Crohn’s disease,  but  it  is  also  useful  for  surveillance  of  patients  with  Peutz-Jeghers  syndrome,
while CTE  is  very  accurate  in  small  bowel  tumours  and  in  established  Crohn’s  Disease,  and  its
use in  patients  presenting  with  gastrointestinal  bleeding  is  increasing.  MRE,  an  expensive  and
not widely  available  technique,  is  essential  for  the  study  of  patients  with  Crohn’s  Disease,  and
presents  an  attractive  alternative  to  SBCE  in  Peutz-Jeghers  syndrome  surveillance.
These diagnostic  modalities  are  often  not  competitive  but  synergistic  techniques.  Knowing
their characteristics,  strengths  and  limitations,  indications,  contraindications  and  potential
complications,  as  well  as  the  adaptation  to  local  availability  and  expertise,  is  essential  to
better select  which  procedures  to  perform  in  each  patient,  both  safely  and  effectively,  in  order
to optimize  management  and  improve  patient  outcomes.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier
an  open  access  article  under  the  CC  BY-NC-ND  license
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Cápsula  Endoscópica  e  Estudos  Imagiológicos  Contrastados:  Diferentes  Perspectivas
para  uma  Imagem  Mais  Completa  do  Intestino  Delgado
Resumo  A  investigac¸ão  do  intestino  delgado,  previamente  difícil  e  limitada,  sofreu  uma
revoluc¸ão com  o  aparecimento  de  técnicas  imagiológicas  contrastadas  de  elevada  qualidade,
como a  enterograﬁa  por  tomograﬁa  axial  computadorizada  (enteroTC)  e  a  enterograﬁa  por
ressonância magnética  (enteroRM),  assim  como  pela  enteroscopia  por  cápsula  (EC).
A decisão  na  escolha  da  técnica  a  utilizar  nas  diferentes  patologias  do  intestino  delgado  não
é na  maioria  das  vezes  simples  ou  óbvia.  Adicionalmente,  a  presenc¸a  de  contraindicac¸ões  pode
restringir o  uso  destas  técnicas  em  alguns  doentes,  e  apesar  de  não  serem  consideradas  técnicas
invasivas, não  são  isentas  de  riscos  e  complicac¸ões.
A EC  tem  um  papel  crucial  na  investigac¸ão  da  hemorragia  digestiva  de  causa  obscura  e  da
doenc¸a de  Crohn,  mas  tem-se  revestido  também  de  utilidade  na  vigilância  de  doentes  com
síndrome  de  Peutz-Jeghers;  a  enteroTC  revelou  uma  elevada  capacidade  diagnóstica  para  neo-
plasias do  intestino  delgado  e  na  doenc¸a  de  Crohn  estabelecida,  e  a  sua  utilizac¸ão  na  hemorragia
digestiva de  causa  obscura  tem  vindo  a  expandir.  A  enteroRM,  apesar  de  dispendiosa  e  de
disponibilidade  limitada,  tem  uma  elevada  eﬁcácia  no  estudo  da  doenc¸a  de  Crohn,  e  é  uma
alternativa válida  à  EC  no  síndrome  de  Peutz-Jeghers.
Estas  técnicas  diagnósticas  são  frequentemente  singergísticas  e  complementares,  ao  invés  de
competitivas.  O  reconhecimento  das  suas  características,  das  suas  capacidades  e  limitac¸ões,
assim como  das  indicac¸ões,  contraindicac¸ões  e  potenciais  complicac¸ões,  e  aliado  à  adaptac¸ão
à disponibilidade  e  competências  locais,  é  essencial  na  correcta  escolha  de  procedimentos
seguros e  eﬁcazes  para  cada  doente,  de  forma  a  optimizar  a  abordagem  e  o  prognóstico.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier
España, S.L.U.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
t
d
l
a
c
-
s
ﬂ
a
C
n
A
o
i
o
s
t
a
c
t
b
t
g
i
i1. Introduction
The  study  of  the  small  bowel  has  been  traditionally  limited
to  low  yield  techniques,  such  as  push  enteroscopy  and  small
bowel  follow-through,  or  invasive  techniques  such  as  intra-
operative  enteroscopy.
By  the  end  of  the  past  century,  cross-sectional  imaging
techniques  with  excellent  resolution,  namely  CT  enterog-
raphy  (CTE)  and  magnetic  resonance  enterography  (MRE),
were  developed  to  better  observe  and  characterize  small
bowel  pathology,  while  a  new  contender,  small  bowel  cap-
sule  endoscopy  (SBCE)  has  been  shown  to  provide  excellent
diagnostic  yield  in  a  myriad  of  small  bowel  diseases.
The  choice  of  what  technique  or  even  which  combina-
tion  to  use  for  small  bowel  study  in  the  different  clinical
settings  encountered  daily  is  often  challenging,  and  depends
on  technical  characteristics  but  also  on  local  expertise  and
availability.
2. Technical characteristics
CTE  was  developed  in  1997  to  better  assess  small  bowel
Crohn’s  Disease  (CD).1 The  preparation  for  CTE  includes  a
clear  liquid  diet  for  the  4--6  h  previous  to  the  examina-
tion,  as  well  as  the  administration  of  1000--2000  cc  of  an
oral  contrasting  agent,  usually  over  45--60  min,  followed  by
intravenous  contrast  during  image  acquisition.2 Oral  con-
trast  is  used  in  order  to  accomplish  bowel  distension  and
maximize  the  contrast  between  the  lumen  and  the  bowel
wall.2 CT  enteroclysis,  where  oral  contrast  is  administered
e
(
shrough  a  nasojejunal  tube,  allows  for  superior  jejunal
istension,3 but  poor  patient  tolerance  and  low  efﬁciency
imits  its  use.2 A  number  of  oral  neutral  contrasting  agents
re  available,  including  methylcellulose,  polyethylene  gly-
ol,  manitol,  low-density  barium  solution  and  water  alone
-  the  latter  is  rapidly  absorbed,  resulting  in  poor  disten-
ion,  particularly  in  the  distal  ileum,  and  may  contribute  to
uid  overload.2 For  the  intravenous  contrast,  100--150  cc  of
n  iodine-based  contrasting  agent  is  used,  and  as  in  regular
T,  caution  should  be  employed  in  the  prevention  of  iodine
ephropathy,  particularly  in  diabetic  and  elderly  patients.2,4
 prokinetic,  such  as  metoclopramide  (10--20  mg  po),  is
ften  administered  at  the  start  of  the  oral  contrasting  agent
ngestion,  and  hyoscine  butylbromide  (20  mg  iv)  at  the  start
f  the  intravenous  contrasting  agent  in  order  to  reduce  peri-
talsis  imaging  artefacts.2
MRE  was  more  recently  made  available  to  clinicians,  but
he  same  core  principles  apply  in  regards  to  CTE.  After
 4--6  h  fast,  1000--2000  cc  of  a  biphasic  water-based  oral
ontrast  similar  to  the  ones  used  during  CTE  is  adminis-
ered,  often  with  metoclopramide  (10--20  mg  po),  followed
y  a  gadolinium-based  intravenous  contrast  (0.65  mg/kg)
ogether  with  either  hyoscine  butylbromide  (20  mg  iv)  or
lucagon  (0.5  mg  iv).5,6
Small  bowel  capsule  endoscopy  (SBCE)  was  ﬁrst  unveiled
n  2001.7 For  the  procedure,  ESGE  guidelines  support  the
ndication  for  a  clear  liquid  diet  on  the  day  preceding  the
xam,  as  well  as  a  12  h  fast.7 A  purgative  bowel  preparation
commonly  using  1000--3000  cc  polyethylene  glycol-based
olutions)  is  often  administered  before  capsule  ingestion  as
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t  was  shown  to  signiﬁcantly  improve  the  diagnostic  yield  (OR
.68;  95%  CI  1.16--2.42).8 Just  as  well,  the  antifoaming  agent
imethicone  (300  mg  po  before  capsule  ingestion)  results  in
 signiﬁcantly  better  mucosal  visualization  by  reducing  the
resence  of  air  bubbles  inside  the  intestinal  lumen.8--10 To
revent  incomplete  SBCE,  domperidone  (10  mg  po)  has  been
dvocated,  for  its  use  was  signiﬁcantly  associated  with  a
igher  rate  of  procedure  completion  by  reducing  gastric
ransit  time,11 despite  the  fact  that  newer  capsules,  with
rolonged  battery  duration,  may  in  the  future  obviate  the
eed  for  prokinetics  in  SBCE.12
. Contraindications and complications
mmediate  complications  related  to  CTE  and  MRE  are  rare,
nd  most  frequently  associated  with  intravenous  contrast
dministration.  When  transient  physiologic  responses  to  the
ontrast  (e.g.  localized  warmth  sensation)  were  excluded,
mmediate  adverse  reactions  following  intravenous  contrast
dministration  were  recently  reported  to  be  as  low  as
,6%13,14 in  two  large  series  of  paediatric  and  adult  popu-
ations,  and  resolved  without  complications  after  prompt
reatment  administration  (corticosteroids  or  epinephrine)  in
he  vast  majority  of  the  cases.  Moreover,  severe  adverse
ffects  are  rare  (<1  in  1000),13,14 and  a  large  scale  Japanese
tudy  showed  no  deaths  attributed  to  adverse  reactions
o  intravenous  ﬂuid  injection  in  170,000  patients.15 Nev-
rtheless,  history  of  asthma,  allergy  requiring  medication
r  previous  allergic  reaction  to  the  contrast  should  alert
he  clinician  to  either  avoid  administration  of  the  contrast
r  consider  the  use  of  premedication  with  corticosteroids,
s  well  as  having  the  equipment  for  resuscitation  made
vailable.15 Contrast  nephropathy  occurs  in  1.6--2.3%  of  the
atients,16 but  this  risk  is  sharply  increased  in  patients  with
mpaired  renal  function,  diabetes  or  elderly  age.
Delayed  complications  may  occur  in  up  to  50%  of  the
atients,2,17 including  skin  rash,  fever,  musculoskeletal
ain,  nausea,  vomit,  while  very  late  adverse  reactions  are
are  but  signiﬁcant,  such  as  iodine-based  thyrotoxicosis
nd  gadolinium-associated  nephrogenic  systemic  ﬁbrosis.
umulative  ionizing  radiation  exposure  constitutes  another
omplication  of  CTE.  In  fact,  up  to  2%  of  the  neoplasia
ncidence  may  be  due  to  radiation,  and  the  lifetime  risk
f  neoplasia  resulting  of  CT  procedures  is  2--4  in  10,000
atients.18 This  risk  is  dose  but  also  age-related,  with  the
aediatric  population  representing  the  highest  risk  group,
nd  patients  aged  over  40  having  a  very  low  risk  of  future
T  radiation  implications.19
With  capsule  endoscopy,  the  most  frequently  observed
omplication  is  capsule  retention,  deﬁned  as  the  pres-
nce  of  the  capsule  within  the  patient’s  bowel  after  14
ays  of  capsule  ingestion,  with  an  overall  incidence  of
--2%.20 Such  risk  is  very  low  among  healthy  volunteers,  as
ell  as  in  patients  presenting  with  OGIB  or  suspected  CD,
ut  increased  in  patients  with  history  of  NSAID  consump-
ion,  abdominal  surgery  or  radiation,  and  particularly  in
atients  with  established  CD  or  small  bowel  neoplasias,  in
hich  the  incidence  of  retention  may  reach  13%  and  25%,
espectively.7,20,21 Other  complications,  such  as  bowel  per-
oration  or  capsule  aspiration,  are  exceedingly  rare.22,23
n
e
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Current  capsule  endoscopy  guidelines  consider  the
ollowing  as  contraindications  to  capsule  endoscopy:  preg-
ancy,  suspected  bowel  obstruction,  swallowing  disorders
nd  imminent  MRI  procedure.7,21 Nevertheless,  there  is
 possibility  for  endoscopic  placement  of  the  capsule  in
he  duodenum  for  patients  with  swallowing  disorders,21
hich  should  also  be  considered  in  patients  with  pre-
ious  gastric  surgery  (e.g.  partial  gastrectomy  with
illroth  II  anastomosis)24 and  patients  with  delayed  gastric
mptying.21 Additionally,  no  complications  were  reported
n  pregnant  women  submitted  to  SBCE  during  the  ﬁrst
rimester,7 and  in  certain  settings,  SBCE  was  proven  to
e  safe  and  feasible  even  in  patients  with  known  small
owel  stenoses.25 Finally,  paediatric  age21 and  pacemakers
r  implantable  cardioverter  deﬁbrillators7,26 are  no  longer
onsidered  contraindications  to  SBCE.
Pregnancy  is  also  a  contraindication  to  CTE,  not  only
econdary  to  ionizing  radiation,18 but  because  iodinated
ontrast  may  depress  neonatal  thyroid  function,27 as  well
s  to  MRE,  due  to  concerns  regarding  the  teratogenic  poten-
ial  of  gadolinium.27 Other  contraindications  to  CTE  include
nown  allergy  to  iodine-based  contrast14 and  impaired  renal
unction18;  young  age,  particularly  in  the  setting  of  inﬂam-
atory  bowel  diseases  or  Peutz-Jeghers  syndrome,  where
ultiple  small  bowel  evaluations  are  warranted  throughout
 lifetime,  may  also  constitute  a  relative  contraindication
o  CTE.28,29 MRE  is  contraindicated  in  patients  with  metallic
oreign  objects  and  depressed  renal  function,30 but  may  be
sed  in  claustrophobic  and  younger  patients  if  light  sedation
s  available.30
. Inﬂammatory bowel disease
oth  cross-sectional  imaging  and  SBCE  have  uses  in  a  mul-
itude  of  diseases,  but  nowhere  is  the  clinical  decision  of
hich  technique  to  employ  more  frequent  and  inﬂuential
han  on  patients  with  inﬂammatory  bowel  diseases.
CTE  exhibits  high  spatial  resolution,  allowing  for  accu-
ate  imaging  of  mural  and  extra-luminal  diseases,  especially
hen  a  multidetector  row  is  used.2,4 The  sensitivity  for
TE  in  the  context  of  established  CD  is  up  to  90%,31,32 and
ypical  radiological  ﬁndings  include  mucosal  hyperenhance-
ent,  mural  thickening  (>3--4  mm  is  considered  abnormal,
nd  up  to  2  cm  may  be  observed  in  CD),  ulceration,  mesen-
eric  inﬂammation  and  engorgement  of  vasa  recta  (resulting
n  the  classical  ‘‘comb  sign’’)2,33;  extra-luminal  CD  ﬁnd-
ngs,  such  as  abdominal  abscesses  and  ﬁstulae  may  also  be
bserved  and  characterized.2 Likewise,  MRE  allows  for  the
iagnosis  of  both  intestinal  and  extra-intestinal  abnormali-
ies  in  CD,  and  the  radiological  ﬁndings  are  similar  between
he  two  techniques.  MRE,  in  particular,  exhibits  a  very  high
ensitivity  and  speciﬁcity  (up  to  84%  and  100%,  respectively)
n  the  evaluation  of  intra-abdominal  ﬁstulae.4 A  common
oncern  among  CD  patients  submitted  to  CTE  is  the  cumu-
ative  radiation  exposure,  particularly  as  these  patients  are
ften  of  younger  age  and  present  with  multiple  relapses  of
isease  activity.4CD  is  one  of  the  main  indications  for  SBCE,  both  for  diag-
osis  as  well  as  for  known  disease.  It  allows  for  mucosal
valuation  of  the  entire  small  bowel,  and  for  the  detection
f  CD  lesions  such  as  villous  oedema,  erosions,  ulcers  and
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stenoses.7 SBCE  has  been  shown  to  display  a  high  sensitivity
for  CD,  signiﬁcantly  superior  to  other  diagnostic  modalities,
including  both  CTE34 and  MRE,35 particularly  for  proximal
and  superﬁcial  lesions,35,36 resulting  in  a  very  high  negative
predictive  value,  ranging  from  96  to  100%.37 In  fact,  SBCE
has  recently  been  shown  to  be  equivalent  to  ileocolonoscopy
in  the  diagnostic  yield  of  small  bowel  CD.38 Furthermore,
inﬂammatory  activity  on  the  proximal  small  bowel  detected
on  SBCE  has  been  shown  to  have  a  signiﬁcant  impact  on
disease  course  and  was  independently  associated  with  a  sig-
niﬁcant  risk  of  relapse,39 and  directly  contributed  to  changes
in  the  therapeutical  approach  in  up  to  30%  of  patients  with
known  CD.40 Inﬂammatory  activity  scores  such  as  the  CEC-
DAI  (or  Niv  Score)41 and  the  Lewis  Score42--44 have  been
developed  and  validated  in  order  to  quantify  inﬂammation
severity,  extent  and  distribution.41,43
Nevertheless,  when  compared  to  both  CTE  and  MRE,  SBCE
presents  a  lower  speciﬁcity,33,45 in  part  due  to  the  fact  that
up  to  20%  of  healthy  subjects  may  present  small  bowel  ero-
sions  during  SBCE,46 but  also  because  small  bowel  lesions
akin  to  CD  may  be  encountered  in  other  entities,  such  as
during  non-steroidal  anti-inﬂammatory  drug  use.47 Addition-
ally,  SBCE  in  the  setting  of  established  CD  is  usually  limited
to  patients  with  non-stricturing  non-penetrating  diseases,
although  recent  evidence  suggests  that  the  capsule  may  be
able  to  traverse  CD  small  bowel  stenoses  in  the  majority
of  the  patients.25 The  use  of  the  patency  capsule,  a  device
with  dissolvable  components  precluding  the  occurence  of
obstruction,  identiﬁes  patients  with  an  increased  risk  of
SBCE  retention,  and  it  is  currently  recommended  by  the
ESGE  guidelines  before  performing  SBCE  in  patients  with
established  CD.47
In  patients  with  suspected  CD  with  a  negative  ileo-
colonoscopy,  current  ECCO48 and  ESGE47 guidelines  consider
SBCE  to  be  a  ﬁrst-line  examination  in  the  absence  of
obstructive  symptoms,  whereas  in  such  patients,  cross-
sectional  imaging  should  be  preferred.  On  the  other  hand,  in
patients  with  established  CD,  cross-sectional  imaging,  with
the  potential  to  assess  both  intestinal  and  extra-intestinal
disease,  should  be  the  modality  of  choice  to  evaluate  the
small  bowel,  preferably  MRE  due  to  absence  of  ionizing  radi-
ation.  SBCE  should  be  reserved  to  patients  with  unexplained
symptoms  or  OGIB,  when  MRE/CTE  are  inconclusive.
5. Obscure gastrointestinal bleeding
OGIB  has  been  deﬁned  as  bleeding  of  unknown  origin
that  persists  or  recurs  after  a  negative  initial  endoscopy
study  (esophagogastroduodenoscopy  and  colonoscopy).49
OGIB  may  be  responsible  for  up  to  5%  of  all  gastrointestinal
haemorrhage,50 and  in  the  vast  majority  of  the  cases,  origi-
nates  within  the  small  bowel.7 Currently,  SBCE  is  considered
to  be  the  ﬁrst-line  investigation  in  patients  presenting  with
OGIB,47 demonstrating  very  high  sensitivity  and  speciﬁcity
(up  to  95%  and  75%,  respectively)  when  compared  to  the  gold
standard  of  intraoperative  enteroscopy,51 and  resulting  in
clinical  management  changes  in  two  thirds  of  the  patients.52The  diagnostic  yield  of  SBCE  in  OGIB  has  been  reported
to  be  up  to  60%  in  recent  meta-analysis  and  system-
atic  reviews,20,53 signiﬁcantly  superior  to  other  diagnostic
modalities,  such  as  push-enteroscopy  (56%  vs.  26%)54 and
s
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ngiography  (53%  vs.  20%)55 and  non-inferior  to  double  bal-
oon  enteroscopy  (62%  vs.  56%).53 Independent  risk  factors
ssociated  with  an  increased  diagnostic  yield  of  SBCE  in
GIB  include  the  presence  of  overt  OGIB,56 shorter  inter-
al  between  presentation  and  the  procedure,57 recurrent
GIB  with  >6  months  of  duration  or  more  than  one  bleed-
ng  episode,21 advanced  age50 and  antithrombotic  use.58 The
iagnostic  yield  may  be  further  improved  by  the  use  of
hromoendoscopy  techniques,  such  as  the  Flexible  Spectral
maging  Colour  Enhancement  (FICE,  Fujinon  Corporation®,
aitama,  Japan),  incorporated  in  Given  Imaging® (Yoqneam,
srael)  software,  that  enhance  surface  patterns  to  better
bserve  mucosal  lesions,59--61 and  the  use  of  such  techniques
hould  be  considered  in  patients  where  a  strong  suspicion  for
mall  bowel  abnormalities  remain  despite  a  negative  SBCE.
Nevertheless,  a negative  SBCE  does  not  always  preclude
mportant  small  bowel  lesions,  and  while  OGIB  recurrence
as  been  shown  to  be  less  likely  in  this  setting,62 a  recent
tudy  reported  rebleed  rates  of  up  to  25%  during  long-term
ollow-up.63 In  these  patients,  further  investigation  may  be
arranted,  and  CTE  presents  as  a  valid  alternative.  Stud-
es  have  shown  that  SBCE  is  associated  with  an  increase
n  diagnostic  yield  of  20--40%64,65 when  compared  to  CTE,
nd  this  advantage  was  even  more  pronounced  in  superﬁ-
ial  lesions  with  no  luminal  repercussion,  such  as  vascular
alformations,65 the  most  frequently  observed  origin  of
GIB  (20--55%).66 However,  CTE  may  be  the  superior  diag-
ostic  modality  in  some  cases,  particularly  during  massive
vert  OGIB,  where  SBCE  may  be  unable  to  locate  or  deﬁne
he  origin  of  the  bleeding,67 and  in  patients  with  small  bowel
umours.68
Few  studies  have  reported  on  the  usefulness  of  MRE  in  the
ontext  of  OGIB,  but  its  use  it  limited  by  a  lower  spatial  reso-
ution  than  CTE,5 reduced  availability  in  the  urgent  setting,6
nd  cost.69 When  compared  to  SBCE,  MRE  demonstrated  a
igniﬁcantly  inferior  diagnostic  yield  (53%  vs.  21%).70
.  Small bowel tumours and Peutz-Jeghers
yndrome
mall  bowel  tumours  are  rare,  accounting  for  less  than
%  of  gastrointestinal  neoplasias  and  less  than  0.5%  of  all
umours.5,7,71 The  most  common  indication  for  investigation
n  patients  presenting  with  small  bowel  tumours  is  OGIB,
n  70  to  90%  of  the  cases.7 In  fact,  small  bowel  tumours  are
esponsible  for  OGIB  in  10--20%  of  the  patients,  second  in  fre-
uency  to  vascular  malformations,  and  ahead  of  CD  (2--10%)
nd  NSAID  enteropathy  (5%).66 Moreover,  in  patients  under
0  years,  small  bowel  tumours  overcome  vascular  malforma-
ions  as  the  leading  cause  of  OGIB  originating  in  the  small
owel.66
Nevertheless,  a low  prevalence  of  small  bowel  tumours,
oupled  with  their  predominant  location  in  the  jejunum,
onspeciﬁc  presentation  of  OGIB,  abdominal  pain  and
eight  loss,  frequently  leads  to  delayed  investigation  and
dvanced  neoplasia  at  diagnosis.71
The  advent  of  SBCE  allowed  a  paradigm  shift,  and  recent
tudies  have  shown  SBCE  to  detect  small  bowel  neoplasia  in
atients  with  a  previous  work-up  of  2--4  procedures,71 and
mpact  management  decision  in  55--80%  of  the  cases.71,72
here  are,  however,  limitations  to  SBCE  in  the  diagnosis  of
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Table  1  First-line  diagnostic  procedure(s)  for  the  investi-
gation  of  the  small  bowel.
Clinical  setting  First-line  diagnostic
procedure(s)
Suspected  Crohn’s
disease
SBCE
MRE  (if  suspected  obstruction)
CTE  (risk  of  cumulative  ionizing
radiation)
Established
Crohn’s  disease
MRE
CTE  (risk  of  cumulative  ionizing
radiation)
SBCE  (if  obstruction  unlikely)
OGIB  SBCE
CTE  (if  age  ≤40  years)
Suspected  small
bowel  tumours
CTE
PJS  surveillance  MRE
SBCE
f
a
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characteristics,  strengths  and  limitations,  indications  and
contraindications,  as  well  as  the  adaptation  to  local  avail-2  
mall  bowel  tumours:  SBCE  exhibits  a  false  negative  rate
f  up  to  66%  in  the  proximal  small  bowel  or  in  submu-
osal  lesions,  even  in  large  and  protruding  lesions,73 because
f  limited  ﬁeld  of  vision,  folds  and  loop  angulations,  poor
owel  preparation,  rapid  transit  time,  non-continuous  image
apture  and  incomplete  examination;  additionally,  SBCE  is
nable  to  adequately  characterize  both  the  size  and  the
ocation  of  the  tumour,21,73 and  presents  a  retention  rate
f  up  to  25%  in  such  patients.7
CTE  sensitivity  and  speciﬁcity  for  small  bowel  tumours
ave  been  reported  to  be  up  to  93%  and  99%,  respectively.2,74
urthermore,  CTE  is  able  to  adequately  locate  and  char-
cterize  both  location,  size,  extra-intestinal  invasion  and
etastatic  disease  (lymphatic  and  disseminated).74 In  a
ecent  prospective  study,  CTE  with  a  64-section  multide-
ector  row  demonstrated  a  superior  diagnostic  yield  when
ompared  to  SBCE  (88  vs.  38%),  and  this  difference  largely
esulted  from  the  detection  of  100%  of  small  bowel  tumours
ompared  to  only  33%  observed  with  SBCE,68 and  these
esults  were  replicated  in  other  published  reports.2,5,74 As
 result,  CTE  should  be  considered  as  a  valid  alternative
o  SBCE  as  a  ﬁrst  line  diagnostic  procedure  in  younger
atients  presenting  with  OGIB,  a  population  where  small
owel  tumours  are  the  most  prevalent  ﬁnding.66
The  use  of  MRE  for  small  bowel  tumour  diagnosis  is
imited  due  to  its  lower  spatial  resolution  and  susceptibil-
ty  for  movement  artefacts,  but,  similarly  to  CTE,  it  allows
or  the  tumour  characterization,  as  well  as  the  assessment
f  metastatic  disease.5,6
Peutz-Jeghers  syndrome  (PJS)  is  an  autosomal  dominant
ondition  presenting  with  mucocutaneous  pigmentation  and
astrointestinal  hamartomatous  polyps.29 Almost  90%  of  PJS
atients  present  with  small  bowel  polyps,  and  the  chief
ndication  for  small  bowel  surveillance  is  the  signiﬁcantly
ncreased  risk  of  intussusception,75 particularly  in  larger
olyps76 --  by  age  20,  intussusception  has  occurred  in  half
he  patients  with  PJS,  and,  in  the  majority  of  them,  pre-
ented  with  acute  abdomen  requiring  surgical  approach.77In
he  European  Mallorca  consensus  of  2007,  the  decision  was
ade  to  use  SBCE  in  the  screening  and  surveillance  of  PJS
very  2--3  years  after  8  years  of  age  and  in  symptomatic
atients,76 and  these  recommendations  were  adapted  and
ncorporated  in  the  recently  published  ACG  guidelines  on
he  management  of  hereditary  gastrointestinal  cancer  syn-
romes,  allowing  for  the  second  small  bowel  SBCE  to  be
elayed  until  the  age  of  18,  if  the  ﬁrst  SBCE  detected  no
olyps,  and  no  symptoms  developed.77
Nevertheless,  SBCE  has  been  shown  to  miss  the  detection
f  up  to  20--40%78,79 of  PJS  small  bowel  polyps,  includ-
ng  large  polyps78 as  well  as  those  in  the  proximal  small
owel.79,80 Recently,  a  number  of  authors  have  reported
uperior  capabilities  of  SBCE  versus  MRE  in  polyps  <10  mm,81
quivalence  of  both  techniques  in  polyps  10--15  mm,81,82 but
rucially,  MRE  superiority  in  diagnostic  yield,  as  well  as
etter  size  and  location  estimation,  in  larger  small  bowel
olyps.29,47,81,82 This  advantage  of  MRE  was  not  observed
n  another  prospective  study,  where  a  polyp  of  30  mm  was
issed  by  MRE,  and  identiﬁed  during  SBCE.83 Thus,  current
SGE  guidelines  consider  small  bowel  surveillance  to  be  ade-
uate  with  both  SBCE  and  MRE,  depending  on  availability  and
ocal  expertise.47
a
o
o
aNo  role  exists  for  CTE  in  PJS,  due  to  the  repeated  need
or  small  bowel  assessment  in  young  patients,  resulting  in
n  unacceptable  ionizing  radiation  exposure.29
. Conclusion
n  conclusion,  SBCE  remains  the  ﬁrst-line  examination  for
GIB,  and  plays  a  key  role  in  the  diagnosis  of  CD,  as  well
s  the  surveillance  of  PJS.  Its  use  on  small  bowel  tumours
nd  established  CD,  however,  should  be  reserved  to  selected
ases  due  to  the  risk  of  retention  and  inability  to  precisely
eﬁne  location  and  extra-intestinal  involvement  of  either
athology.
CTE  has  proven  to  be  the  most  effective  modality  in  the
tudy  of  small  bowel  tumours,  and  may  be  used  in  the  diag-
ostic  work-up  of  OGIB  in  patients  where  this  diagnosis  is
ore  likely  to  occur.  CTE  should  also  be  considered  both  in
uspected  and  established  CD,  but  ionizing  radiation  expo-
ure  should  pose  concerns,  particularly  in  younger  patients.
Finally,  the  importance  of  MRE  in  the  study  of  CD  is
rowing  as  a  non-invasive  non-ionizing  technique  with  the
ossibility  to  characterize  both  mucosal  injury  and  pene-
rating  disease,  and  provides  an  alternative  to  SBCE  in  PJS
atients.  Nevertheless,  local  expertise  and  availability  is
symmetric,  and  a  limitation  to  the  broad  use  of  this  tech-
ique.  Table  1  summarizes  the  main  indications  for  SBCE,
TE  and  MRE,  as  well  as  the  ﬁrst-line  modalities  for  each
linical  setting.
In clinical  practice,  SBCE,  CTE  and  MRE  are  often  not  com-
etitive  but  synergistic  techniques;  the  knowledge  of  theirbility  and  expertise,  is  crucial  to  select  the  best  sequence
f  examinations  for  each  speciﬁc  situation,  in  order  to
ptimize  diagnostic  algorithms  and  ultimately  clinical  man-
gement  and  outcomes.
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